Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Amortization of Deferred Charges (2020 - 2021)

Foghorn Therapeutics (FHTX) has 2 years of Amortization of Deferred Charges data on record, last reported at $58000.0 in Q4 2021.

  • For Q4 2021, Amortization of Deferred Charges fell 1.69% year-over-year to $58000.0; the TTM value through Sep 2022 reached $58000.0, down 81.82%, while the annual FY2021 figure was $318000.0, 33.61% up from the prior year.
  • Amortization of Deferred Charges reached $58000.0 in Q4 2021 per FHTX's latest filing, down from $88000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $88000.0 in Q3 2021 and bottomed at $53000.0 in Q3 2020.